Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonafexor - ENYO Pharma

Next Previous
Search
Drug Profile

Vonafexor - ENYO Pharma

Alternative Names: EYP 001; EYP001a; PXL 007

Latest Information Update: 12 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poxel
  • Developer ENYO Pharma; Poxel; PRA Health Sciences
  • Class Antivirals; Benzopyrans; Carboxylic acids; Chlorobenzenes; Hepatoprotectants; Piperazines; Small molecules; Sulfones
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hereditary nephritis; Kidney disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Jun 2024 Phase-II clinical trials in Hereditary nephritis (In adolescents, In adults) in USA (PO) (NCT06425055)
  • 16 Jan 2024 Phase-II clinical trials in Kidney disorders (unspecified route) (Enyo Pharma pipeline, January 2023)
  • 03 Jan 2024 US FDA approves IND application for Vonafexor in Alport syndrome

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top